According to the suit, PTC Therapeutics received a Refuse to File letter from the United States FDA regarding PTC's New Drug Application ("NDA") for Translarna™ (ataluren), an oral, first-in-class, protein restoration therapy for the treatment of nonsense mutation Duchenne muscular dystrophy. The FDA's Refuse to File letter stated that the application was not sufficiently complete to permit a substantive review.